# A Study to Assess Feasibility of Using Clinician-directed and Digital Application Supported Cognitive Behavior Therapy (CBT) in Conjunction With Esketamine in Participants With Treatment-resistant Depression

> **NCT05268497** · PHASE1 · WITHDRAWN · sponsor: **Janssen Research & Development, LLC**

## Conditions studied

- Depression

## Interventions

- **DRUG:** Esketamine
- **BEHAVIORAL:** Cognitive Behavioral Therapy (CBT)
- **DRUG:** Antidepressant

## Key facts

- **NCT ID:** NCT05268497
- **Lead sponsor:** Janssen Research & Development, LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2022-09-01
- **Primary completion:** 2023-06-07
- **Final completion:** 2023-06-07
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** due to budget decision and wanting to pursue other research priorities
- **Last updated:** 2025-04-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05268497

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05268497, "A Study to Assess Feasibility of Using Clinician-directed and Digital Application Supported Cognitive Behavior Therapy (CBT) in Conjunction With Esketamine in Participants With Treatment-resistant Depression". Retrieved via AI Analytics 2026-06-16 from https://api.ai-analytics.org/clinical/NCT05268497. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*